Trial Profile

A phase 3 study of long acting injectable (LAI) formulation of Fanapt

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iloperidone (Primary)
Indications Bipolar disorders; Post-traumatic stress disorders; Psychotic disorders; Schizophrenia
Focus Therapeutic Use

Most Recent Events

13 Feb 2025 Status changed from planning to recruiting. The company initiated this study in the fourth quarter of 2024.
14 May 2024 New trial record
08 May 2024 According to a Vanda Pharmaceuticals media release, company expects to initiate a Phase III program for the long acting injectable (LAI) formulation of Fanapt by the end of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com